Amylyx Pharmaceuticals, Inc. AMLX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -665.00K | -249.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -665.00K | -249.00K |
| Cost of Revenue | 92.45M | 95.90M | 90.40M | 92.08M | 94.27M |
| Gross Profit | -92.45M | -95.90M | -90.40M | -92.75M | -94.52M |
| SG&A Expenses | 69.66M | 63.37M | 62.89M | 64.59M | 66.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 162.10M | 159.27M | 153.29M | 156.68M | 160.52M |
| Operating Income | -162.10M | -159.27M | -153.29M | -157.34M | -160.77M |
| Income Before Tax | -152.05M | -150.07M | -144.69M | -149.92M | -188.24M |
| Income Tax Expenses | 46.00K | 46.00K | 46.00K | -635.00K | -635.00K |
| Earnings from Continuing Operations | -152.09 | -150.11 | -144.74 | -149.28 | -187.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.09M | -150.11M | -144.74M | -149.28M | -187.60M |
| EBIT | -162.10M | -159.27M | -153.29M | -157.34M | -160.77M |
| EBITDA | -161.74M | -158.80M | -152.77M | -156.76M | -160.09M |
| EPS Basic | -1.43 | -1.51 | -1.55 | -1.80 | -2.50 |
| Normalized Basic EPS | -0.93 | -0.97 | -1.00 | -1.22 | -1.33 |
| EPS Diluted | -1.43 | -1.51 | -1.55 | -1.80 | -2.50 |
| Normalized Diluted EPS | -0.93 | -0.97 | -1.00 | -1.22 | -1.33 |
| Average Basic Shares Outstanding | 424.94M | 402.88M | 378.01M | 336.76M | 311.52M |
| Average Diluted Shares Outstanding | 424.94M | 402.88M | 378.01M | 336.76M | 311.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |